三阴性乳腺癌（TNBC）由于其高侵袭性和缺乏治疗选择，仍然是一个巨大的临床障碍。尽管如此，免疫治疗策略的不断发展为解决这一障碍开辟了有希望的途径。这篇综述讨论了 TNBC 的先进免疫疗法，强调了由于肿瘤微环境 (TME) 多样性而进行的个性化干预措施。免疫检查点抑制剂（ICIs）无论作为单药治疗还是与细胞毒性药物一起使用时都具有至关重要的意义。此外，同时抑制多个免疫检查点是增强癌症免疫疗法疗效的有效方法。当 ICI 与 PARP 抑制剂、抗血管生成药物和 ADC（抗体药物偶联物）等靶向治疗相结合时，可以观察到协同效应。新兴策略包括肿瘤疫苗、细胞免疫疗法和溶瘤病毒，利用免疫系统选择性破坏恶性细胞的能力。这篇综述深入研究了 TNBC 免疫疗法开发的多样化前景，为该领域的各种进展提供了细致的见解。此外，免疫治疗干预措施为TNBC带来了希望，需要进一步研究优化。版权所有©2024 Elsevier Ltd.保留所有权利。

Triple-negative breast carcinoma (TNBC) remains a formidable clinical hurdle owing to its high aggressiveness and scant therapeutic options. Nonetheless, the evolving landscape of immunotherapeutic strategies opens up promising avenues for tackling this hurdle. This review discusses the advancing immunotherapy for TNBC, accentuating personalized interventions due to tumor microenvironment (TME) diversity. Immune checkpoint inhibitors (ICIs) hold pivotal significance, both as single-agent therapies and when administered alongside cytotoxic agents. Moreover, the concurrent inhibition of multiple immune checkpoints represents a potent approach to augment the efficacy of cancer immunotherapy. Synergistic effects have been observed when ICIs are combined with targeted treatments like PARP inhibitors, anti-angiogenics, and ADCs (antibody-drug conjugates). Emerging tactics include tumor vaccines, cellular immunotherapy, and oncolytic viruses, leveraging the immune system's ability for selective malignant cell destruction. This review offers an in-depth examination of the diverse landscape of immunotherapy development for TNBC, furnishing meticulous insights into various advancements within this field. In addition, immunotherapeutic interventions offer hope for TNBC, needing further research for optimization.Copyright © 2024 Elsevier Ltd. All rights reserved.